REGENXBIO bets on FDA flexibility with filing plans for Duchenne gene therapy

Details werden geladen...

https://www.biospace.com/drug-development/regenxbio-bets-on-fda-flexibility-with-filing-plans-for-duchenne-gene-therapy

REGENXBIO bets on FDA flexibility with filing plans for Duchenne gene therapy - BioSpace

A few short days after announcing an FDA pivot on a separate asset, REGENXBIO is planning to test the agency’s apparent newfound rare disease outlook on another late-stage gene therapy.

UniQure plans Q3 submission for Huntington’s gene therapy after FDA reverses course—again - BioSpace

https://www.biospace.com/fda/uniqure-plans-q3-submission-for-huntingtons-gene-therapy-after-fda-reverses-course-again

Wagering on FDA changes, Regenxbio will submit Duchenne gene therapy for approval

https://www.statnews.com/2026/06/24/regenxbio-duchenne-gene-therapy-fda-submission/

REGENXBIO to resubmit application for Hunter gene therapy after FDA’s most recent pivot - BioSpace

https://www.biospace.com/fda/regenxbio-to-resubmit-application-for-hunter-gene-therapy-after-fdas-most-recent-pivot

UniQure’s chronic epilepsy gene therapy 'should be on investors’ radar' - BioSpace

https://www.biospace.com/drug-development/uniqures-chronic-epilepsy-gene-therapy-should-be-on-investors-radar

Registrieren

REGENXBIO bets on FDA flexibility with filing plans for Duchenne gene therapy - BioSpace

Ähnliche Seiten

UniQure plans Q3 submission for Huntington’s gene therapy after FDA reverses course—again - BioSpace

Wagering on FDA changes, Regenxbio will submit Duchenne gene therapy for approval

REGENXBIO to resubmit application for Hunter gene therapy after FDA’s most recent pivot - BioSpace

UniQure’s chronic epilepsy gene therapy 'should be on investors’ radar' - BioSpace